A detailed history of Farallon Capital Management LLC transactions in Natera, Inc. stock. As of the latest transaction made, Farallon Capital Management LLC holds 3,927,683 shares of NTRA stock, worth $418 Million. This represents 1.67% of its overall portfolio holdings.

Number of Shares
3,927,683
Holding current value
$418 Million
% of portfolio
1.67%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$59.21 - $92.9 $26.8 Million - $42.1 Million
452,800 Added 13.03%
3,927,683 $359 Million
Q4 2023

Feb 14, 2024

BUY
$37.55 - $62.64 $130 Million - $218 Million
3,474,883 New
3,474,883 $218 Million
Q3 2023

Nov 14, 2023

BUY
$43.4 - $62.52 $98.9 Million - $142 Million
2,277,883 New
2,277,883 $101 Million
Q2 2023

Aug 14, 2023

BUY
$47.08 - $55.16 $31.2 Million - $36.5 Million
662,400 Added 100.09%
1,324,183 $64.4 Million
Q1 2023

May 15, 2023

BUY
$36.57 - $58.29 $19 Million - $30.2 Million
518,583 Added 362.14%
661,783 $36.7 Million
Q4 2022

Feb 14, 2023

SELL
$34.17 - $47.91 $2.9 Million - $4.06 Million
-84,753 Reduced 37.18%
143,200 $5.75 Million
Q3 2022

Nov 14, 2022

SELL
$36.93 - $56.68 $95,981 - $147,311
-2,599 Reduced 1.13%
227,953 $9.99 Million
Q2 2022

Aug 15, 2022

SELL
$28.13 - $44.54 $24.5 Million - $38.8 Million
-870,700 Reduced 79.06%
230,552 $8.17 Million
Q1 2022

May 16, 2022

SELL
$30.32 - $91.33 $11.3 Million - $33.9 Million
-371,463 Reduced 25.22%
1,101,252 $44.8 Million
Q4 2021

Feb 14, 2022

BUY
$86.26 - $119.0 $14.9 Million - $20.5 Million
172,581 Added 13.27%
1,472,715 $138 Million
Q3 2021

Nov 15, 2021

BUY
$100.17 - $126.36 $80.1 Million - $101 Million
800,134 Added 160.03%
1,300,134 $145 Million
Q2 2021

Aug 13, 2021

BUY
$86.05 - $119.72 $43 Million - $59.9 Million
500,000 New
500,000 $56.8 Million

Others Institutions Holding NTRA

About Natera, Inc.


  • Ticker NTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 96,957,400
  • Market Cap $10.3B
  • Description
  • Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...
More about NTRA
Track This Portfolio

Track Farallon Capital Management LLC Portfolio

Follow Farallon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.